Edgewise Therapeutics, Inc. - 8-K Filing

Edgewise Therapeutics sold its muscular dystrophy program for $1.55B upfront plus up to $1.1B in milestones, totaling potential consideration of $2.65B.

SEC EDGAR ·

Tickers: $EWTX

Read the full article at SEC EDGAR

More Regulatory news